header image

Take a look through our annual reports.

How to contact us for media/press enquiries.

Have a comment or question? Get in touch.


Octapharma USA Appoints Senior Biopharmaceutical Executive Richard E. Walters, Jr. as Vice President of Commercial Development


HOBOKEN, N.J. (June 5, 2017) – Octapharma USA has appointed Richard E. Walters, Jr. as Vice President of Commercial Development, assuming immediate responsibility for all U.S. product marketing, commercial development and...

Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®


Lachen, Switzerland, May 22nd 2017: Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to...

FDA Grants Octapharma USA Orphan Drug Designation for Octagam® 10% for the Treatment of Dermatomyositis


HOBOKEN, N.J. (May 17, 2017) – The U.S. Food and Drug Administration (FDA) has granted Octapharma USA orphan drug designation for Octagam® Immune Globulin Intravenous (Human) 10% Liquid for the treatment of dermatomyositis, a...

Octapharma USA Research Results Presented at HTRS Symposium Targeting Major Challenges Facing Hemophilia Patients


Global Clinical Trials Focus on Inhibitor Development, Dosing Frequency

Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’ Program at Hemophilia Federation of America Annual Symposium


HOBOKEN, N.J. (April 7, 2017) – Octapharma USA today sponsored the patient symposium “Hope Ignites: Stories to Inspire,” during the Hemophilia Federation of America (HFA) Annual Symposium in Providence, Rhode Island....

Octapharma USA Grant Supports First National Conference for Type 3 von Willebrand Disease Patients


HOBOKEN, N.J. (March 22, 2017) – Octapharma USA has awarded an educational grant to the Global Blood Disorder Foundation (GBDF) to sponsor the first national conference for patients with Type 3 von Willebrand Disease...

Octapharma Group publishes 2016 annual results reporting revenue of €1.6 billion and operating income of €383 million


Lachen, Switzerland, March 1st, 2017: The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015. Octapharma achieved sales...